Please assess the completion status of the following clinical trial:

Trial Title: Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Each participant must meet all of the following inclusion criteria to be enrolled in the study:~* Female participants 18 years or older~* Previously treated, metastatic or locally recurrent malignancy with 1 of the following diagnoses, which has been confirmed histologically or cytologically: adenocarcinoma of the breast (Phase 1 only), recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Phase 1 and 2)~* In the Phase 1 portion of the study, participants with breast cancer must have received treatment with at least 1 but no more than 4 prior chemotherapy regimens not including regimens received in the neoadjuvant and/or adjuvant setting~* Participants with breast cancer must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1~* No antineoplastic therapy or radiotherapy within 3 weeks before enrollment (2 weeks for regimens with recovery expected within 7 to 14 days) and recovered from toxicities of prior therapy (except alopecia); the participant must have recovered from all treatment-related toxicities and must have evidence of progressive disease (PD) or persistent disease~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Adequate bone marrow, liver and renal function~* Postmenopausal at least 1 year, OR Surgically sterile, OR If childbearing potential, agree to 2 effective methods of nonhormonal contraception, or agree to completely abstain from heterosexual intercourse~* Able to provide written informed consent~* Willing to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures~* Suitable venous access~Specific Inclusion Criteria for participants with Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer:~* Prior treatments must have included a platinum and a taxane; the most recent treatment need not be a platinum-containing or taxane-containing regimen~* Disease must have recurred ≤ 12 months after discontinuation of platinum therapy~* Participants who previously received weekly taxane are potentially eligible, provided that they did not progress during therapy or within 3 months of completing therapy~* Participants with platinum-refractory disease, as defined by progression during primary or subsequent platinum-based therapy or persistent radiographic disease after primary or subsequent platinum-based therapy, will be included~* Participants must have measurable disease in target lesions or assessable disease (defined by cancer antigen-125 - CA-125 per protocol), and disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or modified Gynecologic Cancer Intergroup (GCIG) CA-125 criteria~Exclusion Criteria:~Participants meeting any of the following exclusion criteria are not to be enrolled in the study:~* Prior treatment with an Aurora A-targeted agent (including MLN8237)~* Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of MLN8237 and during the study~* Treatment with more than 4 cytotoxic chemotherapy regimens in the metastatic setting; prior therapy cannot include more than 2 prior taxane-containing regimen. Current use of tamoxifen, thalidomide, or any agent used as maintenance or consolidation therapy for OC.~* Known hypersensitivity to Cremophor® EL, paclitaxel or its components~* Prior history of ≥ Grade 2 neurotoxicity or any toxicity requiring discontinuation from taxane chemotherapy that is not resolved to ≤ Grade 1~* Comorbid or unresolved toxicity that would preclude administration of weekly paclitaxel~* Primary central nervous system malignancy or carcinomatous meningitis~* Symptomatic brain metastasis~* Inability to swallow oral medications or maintain a fast~* History of hemorrhagic or thrombotic cerebrovascular event in past 12 months~* Surgery within 3 weeks before study enrollment and not fully recovered~* Diagnosis or treatment of another malignancy within 2 years preceding first dose of MLN8237 and have any evidence of residual disease except nonmelanoma skin cancer or in situ malignancy completely resected~* Pregnant or lactating~* Serious illness that could interfere with protocol completion~* Investigational treatment 21 days prior to first dose of MLN8237~* Prior allogeneic bone marrow or organ transplantation~* Infection requiring systemic antibiotic therapy within 14 days prior to first dose of MLN8237~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C~* Radiotherapy to \> 25% bone marrow or whole pelvic radiotherapy~* Requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes. Intermittent uses of antacids of H2 antagonists are allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alisertib (Phase 1 - Ovarian cancer) (Type: EXPERIMENTAL): Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
- Alisertib (Phase 1 - Breast cancer) (Type: EXPERIMENTAL): Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
- Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2) (Type: EXPERIMENTAL): Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
- Paclitaxel 80 mg/m^2 (Phase 2) (Type: EXPERIMENTAL): Paclitaxel 80 mg/m\^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).

Based on this trial design, predict the completion outcome and termination type (if applicable).